Connection

Philip Hall to Antineoplastic Agents

This is a "connection" page, showing publications Philip Hall has written about Antineoplastic Agents.
Connection Strength

0.498
  1. Experience with dasatinib and nilotinib use in pregnancy. J Oncol Pharm Pract. 2018 Mar; 24(2):121-128.
    View in: PubMed
    Score: 0.323
  2. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia. 1999 Apr; 13(4):629-33.
    View in: PubMed
    Score: 0.093
  3. The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol. 1995 Nov; 23(12):1256-60.
    View in: PubMed
    Score: 0.074
  4. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.